Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Laurence Rahme
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Spero Therapeutics, In.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Rahme is a co-founder of Spero Therapeutics, Inc. The company is developing novel anti-infectives to treat drug resistant infections. The goal of this R21/R33 research grant is to find drugs that block the conversion of bacterial cells into the persister state that enables them to survive traditional antibiotic treatments and thereby cause persistent and relapsing infections. IP resulting from this grant has been licensed to Spero Therapeutics. The Co-Chairs of Partners HealthCare Committee on Outside Activities evaluated the financial interest in connection with this research and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research. An FCOI management plan was previously implemented for the R21 portion of this grant. The management plan will be continued for the new R33 portion of the grant.
Interruption of Signaling-Mediated Bacterial Persistent Infections
Persistent, chronic, and relapsing infections pose a growing threat to human health worldwide. Such infections are difficult to cure because the bacteria that cause them can survive antibiotic treatments owing to their ability to adopt a persister (dormant-like) state. The goal of this project is to find drugs that block the conversion of bacterial cells into the persister state that enables them to survive traditional antibiotic treatments and thereby cause persistent and relapsing infections.
Filed on April 01, 2015.
Tell us what you know about Laurence Rahme's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Laurence Rahme filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, Inc. | $10,000 - $19,999 |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, In. | $10,000 - $19,999 |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, Inc. | Value cannot be readily determined |
| Laurence Rahme | Massachusetts General Hospital | Conflict of Interest | Spero Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.